Ensayos clínicos

Inclusion Criteria:

• Adults with the established, pathologically confirmed diagnosis of relapsed AML
• AML that has relapsed at least once or is primary induction failure
• Eastern Cooperative Oncology Group (ECOG) performance status 0-2
• Patients must be able to give informed consent
• Female patients of childbearing age must have negative pregnancy test
• Serum creatinine ≤ 2.0 mg/dl
• Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 5 x upper limit normal (ULN), unless due to Gilbert's, hemolysis or leukemic infiltration
• Alkaline phosphatase ≤ 5 x ULN, unless due to Gilbert's, hemolysis or leukemic infiltration
• Bilirubin ≤ 2.0 mg/dl, unless due to Gilbert's, hemolysis or leukemic infiltration
• Left ventricular ejection fraction ≥ 45% by multi gated acquisition scan (MUGA) or echocardiogram
• Baseline Fridericia corrected QT (QTcF) < 480 msec
• Women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for 30 days after study participation; should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately
• Patients who have undergone stem cell transplantation (SCT), autologous or allogeneic, are eligible provided that they are ≥ 4 weeks from stem cell infusion, have no active graft-vs-host disease (GVHD), and meet other eligibility criteria
• Patients who fail primary induction therapy or relapse after achieving complete remission (CR) are eligible if they have undergone no more than 2 prior cytotoxic regimens (a regimen is described as a distinctive planned collection of agent[s] and/or modalities to be utilized together during a cycle or course of therapy; i.e., induction+consolidation with or without stem cell transplant [SCT]), ≥ 2 weeks off cytotoxic chemotherapy, and ≥ 2 weeks off radiation therapy; patients must be off biologic therapies including hematopoietic growth factors ≥ 2 weeks; if using hydroxyurea (HU), steroids, imatinib or other tyrosine kinase inhibitors (TKIs), interferon, or other non-cytotoxics for blast count control, patient must be off for ≥ 24 hours (hrs) before starting MK-8776
• Fluvoxamine and ciprofloxacin must be stopped 7 days prior to day 1 of therapy, and be excluded during administration of study therapy; if the subject is using any of the other drugs that are cytochrome P4501A2 (CYP1A2) or P-glycoprotein (PgP) inhibitors, substitution should be considered and administration of these drugs should be avoided on the days of administration of MK-8776; in addition, smoking should be avoided and cytochrome P450 3A4 (CYP3A4) substrates with a narrow therapeutic index should be avoided: alfentanil, astemizole, cisapride, cyclosporine, diergotamine, ergotamine, fentanyl, pimozide, quinidine, sirolimus, tacrolimus, terfenadine

Exclusion Criteria:

• Any previous treatment with MK-8776
• Considered refractory or treatment failure to most recent treatment regimen, unless primary refractory
• Concomitant chemotherapy, radiation therapy, or immunotherapy
• Hyperleukocytosis with ≥ 50,000 blasts/uL (if using HU, steroids, tyrosine kinase/src inhibitors (including fms-related tyrosine kinase 3 [FLT3] inhibitors), arsenic, interferon or leukapheresis for blast count control, patient must be off those agents for 24 hours prior to beginning ara-C +/- MK-8776)
• Acute progranulocytic leukemia (APL, M3)
• Active disseminated intravascular coagulation (DIC)
• Active central nervous system (CNS) leukemia
• Active, uncontrolled infection; patients with infection under active treatment and controlled with antibiotics are eligible
• Presence of other life-threatening illness
• Patients with mental deficits and/or psychiatric history that preclude them from giving informed consent or from following protocol
• Pregnant women are excluded from this study; breastfeeding should be discontinued if the mother is treated with MK-8776
• History of Fridericia corrected QT (QTcF) prolongation greater than grade 1 or 480 msec
• Subjects with the following cardiac risk factors must be excluded: transmural myocardial infarction (MI) within prior 6 months, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, cerebrovascular accident or transient ischemic attack (TIA) or seizure disorder within 6 months prior to study drug administration
• Subjects with history of risk factors for torsades de pointes: clinical history of heart failure (New York Heart Association [NYHA] class III or IV), hypo- or hyper-kalemia or hypomagnesemia (supplementation to bring levels within normal limits prior to administration of MK-8776 is acceptable) or family history of Long QT Syndrome
• Human immunodeficiency virus (HIV)-positive patients receiving anti-retroviral therapy or who have a prior history of acquired immunodeficiency syndrome (AIDS) indicator conditions, other than history of lymphoma more than 3 years remote